Changes in Inhibition and Valuation After Eating
Launched by ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · Aug 15, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how eating affects decision-making and self-control in women with bulimia nervosa (BN). Researchers want to understand how the act of eating influences thoughts and feelings about control, which may contribute to the cycles of binge eating, purging, and restricting food intake that many individuals with BN experience. By learning more about these patterns, the goal is to find better ways to help treat bulimia nervosa.
Women aged 18 to 45 who are currently experiencing bulimia nervosa may be eligible to participate in this study. Participants should have a body mass index (BMI) between 18.5 and 30 and must be right-handed and English-speaking. During the study, participants will take part in activities related to eating and decision-making, while undergoing brain scans to help researchers gather important information. It’s also important to note that certain health conditions, pregnancy, and allergies to meal ingredients can affect eligibility for the trial.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female
- • Aged 18 to 45 years
- • Current BMI greater than or equal to 18.5kg/m2 but under 30kg/m2
- • Right-handed
- • English-speaking
- Additional Inclusion Criteria for Women with Bulimia Nervosa:
- • Meet DSM-5 criteria for bulimia nervosa
- Exclusion Criteria:
- • Medical instability
- • Ongoing medical treatment, medical condition, or psychiatric disorder that may interfere with study variables or participation
- • Shift work
- • Pregnancy, planned pregnancy, or lactation during the study period
- • Allergy to any of the ingredients in or unwillingness to consume the standardized meal or unwillingness to drink water during the fasting period
- • Any contraindication for fMRI
About Icahn School Of Medicine At Mount Sinai
The Icahn School of Medicine at Mount Sinai is a premier academic institution located in New York City, renowned for its commitment to advancing medical research, education, and patient care. As a leading sponsor of clinical trials, the institution leverages its state-of-the-art facilities and multidisciplinary expertise to drive innovative research initiatives aimed at improving health outcomes. With a focus on translational medicine, the Icahn School of Medicine collaborates with a diverse network of researchers, clinicians, and industry partners to explore novel therapies and interventions across a wide range of medical disciplines. Its rigorous scientific approach and dedication to ethical standards position it as a trusted leader in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Laura A Berner, Ph.D.
Principal Investigator
Mount Sinai Icahn School of Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported